|Other Names||Sentrin-specific protease 3, SUMO-1-specific protease 3, Sentrin/SUMO-specific protease SENP3, SENP3, SSP3, SUSP3|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1235a was selected from the C-term region of human SENP3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Protease that releases SUMO2 and SUMO3 monomers from sumoylated substrates, but has only weak activity against SUMO1 conjugates. Deconjugates SUMO2 from MEF2D, which increases its transcriptional activation capability. Deconjugates SUMO2 and SUMO3 from CDCA8. Redox sensor that, when redistributed into nucleoplasm, can act as an effector to enhance HIF1A transcriptional activity by desumoylating EP300. Required for rRNA processing through deconjugation of SUMO2 and SUMO3 from nucleophosmin, NPM1. Plays a role in the regulation of sumoylation status of ZNF148. Functions as a component of the Five Friends of Methylated CHTOP (5FMC) complex; the 5FMC complex is recruited to ZNF148 by methylated CHTOP, leading to desumoylation of ZNF148 and subsequent transactivation of ZNF148 target genes.|
|Cellular Location||Cytoplasm. Nucleus, nucleolus. Nucleus, nucleoplasm. Note=Mainly found in the nucleoplasm, with low levels detected in the cytoplasmic and chromatin fractions (By similarity). Redistributes between the nucleolus and the nucleoplasm in response to mild oxidative stress.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
SENP3 releases SUMO2 and SUMO3 monomers from sumoylated substrates, but has only weak activity against SUMO1 conjugates. This protein deconjugates SUMO2 from MEF2D, which increases its transcriptional activation capability.
Muller S, et al., Nat Rev Mol Cell Biol. 2001 2(3):202-10 Review.Hochstrasser M. Cell. 2001 107(1):5-8. Review.Kahyo T, et al., Mol Cell. 2001 Sep;8(3):713-8.Yeh ET, et al., Gene. 2000 May 2;248(1-2):1-14. Review.Keane,M.M., et al., Oncogene 18 (22), 3365-3375 (1999)
If you have any additional inquiries please email technical services at email@example.com.